Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM

EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?

Now Viewing

EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process

EP: 5.Reviewing CAR T Mechanism & Treatment Process

EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process

EP: 7.Comanaging Cases of RR/MM in Patients Receiving CAR T

EP: 8.On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives

EP: 9.Expert Insights: 68yM High-Risk R/R MM Post HSCT With Progressive Disease—Next Steps?

EP: 10.Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM

Video content above is prompted by the following:

• Which patients do you think about for chimeric antigen receptor (CAR) T-cell therapy in second-line treatment for relapsed/refractory multiple myeloma (ciltacabtagene autoleucel vs idecabtagene vicleucel)?
• Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T-cell therapy referral?
• How do nonmedical factors (location, money, etc) affect patient selection?